Pharmaceuticals - Portugal

  • Portugal
  • In 2024, the projected revenue in the Pharmaceuticals market in Portugal is expected to reach US$2,480.00m.
  • The largest market within this market is Oncology Drugs, with a projected market volume of US$404.60m in 2024.
  • It is anticipated that the revenue will exhibit an annual growth rate of 4.60% (CAGR 2024-2029), resulting in a market volume of US$3,105.00m by 2029.
  • When compared globally, United States is expected to generate the highest revenue, with US$630.30bn in 2024.
  • Portugal has witnessed a surge in the demand for innovative pharmaceutical products, driven by its growing aging population.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Pharmaceuticals market in Portugal has seen significant growth in recent years.

Customer preferences:
Portuguese consumers are becoming increasingly health-conscious, leading to a higher demand for pharmaceutical products. Additionally, an aging population has resulted in a greater need for medication to treat chronic conditions.

Trends in the market:
The Portuguese government has implemented policies to promote generic drugs and reduce healthcare costs, which has led to an increase in the production and consumption of generic pharmaceuticals. The market has also seen a rise in the use of e-commerce platforms for purchasing medication.

Local special circumstances:
Portugal has a national healthcare system that provides free or low-cost medication to its citizens, which has resulted in a high level of government involvement in the pharmaceutical market. Additionally, the country has a strong tradition of pharmaceutical research and development, with several major companies headquartered in Portugal.

Underlying macroeconomic factors:
The Portuguese economy has experienced significant growth in recent years, leading to an increase in disposable income and consumer spending. This has contributed to the growth of the pharmaceutical market. However, the country also faces challenges such as an aging population and a high level of public debt, which may impact the sustainability of the market in the long term.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Next generation therapy
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)